Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR

Recent advances in cancer immunotherapy have completely revolutionized cancer treatment strategies. Nonetheless, the increasing incidence of immune-related adverse events (irAEs) is now limiting the overall benefits of these treatments. irAEs are well-recognized side effects of some of the most effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Bayless, Nicholas L, Bluestone, Jeffrey A, Bucktrout, Samantha, Butterfield, Lisa H, Jaffee, Elizabeth M, Koch, Christian A, Roep, Bart O, Sharpe, Arlene H, Murphy, William J, Villani, Alexandra-Chloé, Walunas, Theresa L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420733/
https://www.ncbi.nlm.nih.gov/pubmed/34479924
http://dx.doi.org/10.1136/jitc-2021-002627

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420733/
https://www.ncbi.nlm.nih.gov/pubmed/34479924
http://dx.doi.org/10.1136/jitc-2021-002627

Ejemplares similares